Age-related macular degeneration
Therapeutic area
Neurology
Rare disease
Yes
- Definition
- Age-related loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Age-related macular degeneration
- Therapeutic area
- Neurology
- age-related macular degeneration
- AMD
- ARMD
- Senile macular retinal degeneration
- age-related macular degeneration
- macular degeneration, age-related
- Severity
- Severe
- Genetic
- Hereditary
- Neurology
- Ophthalmology
- MONDO ID
- MONDO:0005150
- Parent condition
- MONDO:0002175
Related records
Broader conditions (16)
- Degeneration of macula and posterior pole
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Disorder of orbital region
- Disorder of visual system
- Eye disorder
- Hereditary disease
- Hereditary neurological disease
- Human disease
- Inherited retinal dystrophy
- Macular degeneration
- Nervous system disorder
- Retinal degeneration
- Retinal disorder
Narrower conditions (15)
- Age related macular degeneration 1
- Age related macular degeneration 10
- Age related macular degeneration 11
- Age related macular degeneration 12
- Age related macular degeneration 14
- Age related macular degeneration 2
- Age related macular degeneration 4
- Age related macular degeneration 6
- Age related macular degeneration 7
- Age related macular degeneration 8
- Age related macular degeneration 9
- Dry age related macular degeneration
- Macular degeneration, age-related, 3
- Macular dystrophy with central cone involvement
- Wet macular degeneration
Trials (697)
- "Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study
- 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
- 30g vs 33g Needle for Intravitreal Injections
- A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
- A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
- A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
- A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
- A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
- A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools
- A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
Approved drugs (1)
- Verteporfin
Drugs in development (95)
- Abicipar pegol Phase 3
- Acetylcysteine Phase 3
- Acyclovir sodium Phase 1
- Adalimumab Phase 2
- Aflibercept Phase 3
- AGN-211745 Phase 2
- AL-78898A Phase 2
- Alteplase Phase 2
- Ammonium trichlorotellurate Phase 1
- Anecortave acetate Phase 3
- Anti-GD2 monoclonal antibody 3F8 Phase 2
- Aspirin Phase 3
- Atorvastatin Phase 2
- Avacincaptad pegol Phase 2
- Avacincaptad pegol sodium Phase 2
- Bevacizumab Phase 3
- Bevasiranib Phase 3
- Brolucizumab Phase 3
- Bromfenac Phase 2
- Canakinumab Phase 1
Other linked drugs (8)
- Disitertide
- Gildeuretinol
- Lampalizumab
- Loteprednol etabonate
- Moxifloxacin
- Nesvategrast isobutanolammonium
- Omega-3 fatty acids
- Retinol